rgeted therapy for esophagogastric cancers: a review Review (2462) Total Article Views Authors: Khattak MA, Martin HL, Karapetis CS Published Date May 2012 Volume 2012:5 Pages 91 - 102 DOI: http://dx.doi.org/10.2147/OTT.S25117 Received: 24 February 2012 Accepted: 27 March 2012 Published: 21 May 2012 Muhammad A Khattak,1 Hilary L Martin,2 Christos S Karapetis1,3 1Flinders Medical Centre, Adelaide, South Australia; 2Calvary Hospital, Adelaide, SA, Australia; 3Flinders University, Adelaide, SA, Australia Abstract: The incidence of esophagogastric cancers is increasing rapidly in the Western population. Despite better understanding of the biology and intense research in the treatment of these cancers, the long-term survival remains poor both in the locally advanced and metastatic settings. The addition of combined modality strategies has resulted in modest improvement in 5-year survival rates. A number of biologic agents targeting epidermal-derived growth factor receptor, vascular endothelial derived growth factor and its receptor, and mammalian target of rapamycin (mTOR) are being currently evaluated in Phase II and III clinical trials. Some of these, like trastuzumab, cetuximab, and bevacizumab, have shown promising results. This review provides a brief overview of the recent developments in biologic agents for the treatment of esophagogastric cancers.